ES2568801T3 - Composiciones de anticuerpos anti-VEGFR-3 - Google Patents
Composiciones de anticuerpos anti-VEGFR-3 Download PDFInfo
- Publication number
- ES2568801T3 ES2568801T3 ES11754805.7T ES11754805T ES2568801T3 ES 2568801 T3 ES2568801 T3 ES 2568801T3 ES 11754805 T ES11754805 T ES 11754805T ES 2568801 T3 ES2568801 T3 ES 2568801T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- human
- vegfr
- mouse
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title description 4
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 abstract description 10
- 239000000427 antigen Substances 0.000 abstract description 6
- 102000036639 antigens Human genes 0.000 abstract description 6
- 108091007433 antigens Proteins 0.000 abstract description 6
- 241000282414 Homo sapiens Species 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 17
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 15
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 201000010099 disease Diseases 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 101000851029 Mus musculus Vascular endothelial growth factor receptor 3 Proteins 0.000 description 5
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 5
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108090000143 Mouse Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 108700010039 chimeric receptor Proteins 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100372770 Homo sapiens FLT4 gene Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100372771 Mus musculus Flt4 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000008747 mitogenic response Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38043210P | 2010-09-07 | 2010-09-07 | |
| US380432P | 2010-09-07 | ||
| PCT/US2011/050131 WO2012033696A1 (en) | 2010-09-07 | 2011-09-01 | Anti-vegfr-3 antibody compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2568801T3 true ES2568801T3 (es) | 2016-05-04 |
Family
ID=44584686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11754805.7T Active ES2568801T3 (es) | 2010-09-07 | 2011-09-01 | Composiciones de anticuerpos anti-VEGFR-3 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8481034B2 (enExample) |
| EP (1) | EP2614081B1 (enExample) |
| JP (1) | JP2013538813A (enExample) |
| KR (1) | KR20130042601A (enExample) |
| CN (1) | CN103080133A (enExample) |
| AR (1) | AR082641A1 (enExample) |
| AU (1) | AU2011299443B2 (enExample) |
| BR (1) | BR112013005423A2 (enExample) |
| CA (1) | CA2809375C (enExample) |
| CL (1) | CL2013000607A1 (enExample) |
| CO (1) | CO6690754A2 (enExample) |
| CR (1) | CR20130065A (enExample) |
| DO (1) | DOP2013000039A (enExample) |
| EA (1) | EA023331B1 (enExample) |
| EC (1) | ECSP13012481A (enExample) |
| ES (1) | ES2568801T3 (enExample) |
| GT (1) | GT201300058A (enExample) |
| MA (1) | MA34487B1 (enExample) |
| MX (1) | MX2013002718A (enExample) |
| PE (1) | PE20131328A1 (enExample) |
| PH (1) | PH12013500432A1 (enExample) |
| SG (1) | SG188265A1 (enExample) |
| TW (1) | TWI413527B (enExample) |
| UA (1) | UA109148C2 (enExample) |
| WO (1) | WO2012033696A1 (enExample) |
| ZA (1) | ZA201300804B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014064203A1 (en) | 2012-10-26 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
| KR101521981B1 (ko) * | 2013-07-31 | 2015-05-20 | 가톨릭대학교 산학협력단 | 혈액암 줄기세포 증식 또는 생착 억제용 조성물 |
| EP3244924B1 (en) * | 2015-01-15 | 2021-04-07 | Oncoquest Pharmaceuticals Inc. | Methods of increasing delivery of anti-cancer agents to targets |
| CA3044682A1 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| CN110004167A (zh) * | 2019-04-16 | 2019-07-12 | 中国医学科学院血液病医院（血液学研究所） | 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用 |
| CN111808191A (zh) * | 2020-05-11 | 2020-10-23 | 廊坊天光生物技术有限公司 | 一种用于检测血清中vegf含量的抗体对及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002248372B8 (en) * | 2001-01-19 | 2008-03-20 | Vegenics Limited | FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| CN101277976B (zh) | 2005-10-06 | 2012-04-11 | 伊莱利利公司 | 抗肌抑制素抗体 |
-
2011
- 2011-08-25 AR ARP110103100A patent/AR082641A1/es unknown
- 2011-08-26 TW TW100130812A patent/TWI413527B/zh not_active IP Right Cessation
- 2011-09-01 US US13/223,344 patent/US8481034B2/en active Active
- 2011-09-01 EA EA201390117A patent/EA023331B1/ru not_active IP Right Cessation
- 2011-09-01 JP JP2013527303A patent/JP2013538813A/ja active Pending
- 2011-09-01 CN CN2011800430574A patent/CN103080133A/zh active Pending
- 2011-09-01 EP EP11754805.7A patent/EP2614081B1/en active Active
- 2011-09-01 SG SG2013013107A patent/SG188265A1/en unknown
- 2011-09-01 ES ES11754805.7T patent/ES2568801T3/es active Active
- 2011-09-01 CA CA2809375A patent/CA2809375C/en not_active Expired - Fee Related
- 2011-09-01 MA MA35695A patent/MA34487B1/fr unknown
- 2011-09-01 KR KR1020137005794A patent/KR20130042601A/ko not_active Ceased
- 2011-09-01 BR BR112013005423A patent/BR112013005423A2/pt not_active IP Right Cessation
- 2011-09-01 UA UAA201302462A patent/UA109148C2/uk unknown
- 2011-09-01 WO PCT/US2011/050131 patent/WO2012033696A1/en not_active Ceased
- 2011-09-01 AU AU2011299443A patent/AU2011299443B2/en not_active Ceased
- 2011-09-01 PE PE2013000380A patent/PE20131328A1/es not_active Application Discontinuation
- 2011-09-01 MX MX2013002718A patent/MX2013002718A/es unknown
- 2011-09-01 PH PH1/2013/500432A patent/PH12013500432A1/en unknown
-
2013
- 2013-01-30 ZA ZA2013/00804A patent/ZA201300804B/en unknown
- 2013-02-14 DO DO2013000039A patent/DOP2013000039A/es unknown
- 2013-02-15 CR CR20130065A patent/CR20130065A/es unknown
- 2013-03-04 CL CL2013000607A patent/CL2013000607A1/es unknown
- 2013-03-05 GT GT201300058A patent/GT201300058A/es unknown
- 2013-03-06 EC ECSP13012481 patent/ECSP13012481A/es unknown
- 2013-03-07 CO CO13046124A patent/CO6690754A2/es unknown
- 2013-05-07 US US13/888,716 patent/US8784818B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA023331B1 (ru) | 2016-05-31 |
| CN103080133A (zh) | 2013-05-01 |
| ZA201300804B (en) | 2014-07-30 |
| DOP2013000039A (es) | 2013-04-15 |
| CO6690754A2 (es) | 2013-06-17 |
| AU2011299443A1 (en) | 2013-02-14 |
| PE20131328A1 (es) | 2013-11-18 |
| TWI413527B (zh) | 2013-11-01 |
| US8784818B2 (en) | 2014-07-22 |
| ECSP13012481A (es) | 2015-03-31 |
| SG188265A1 (en) | 2013-04-30 |
| EA201390117A1 (ru) | 2013-06-28 |
| TW201223543A (en) | 2012-06-16 |
| MA34487B1 (fr) | 2013-08-01 |
| US8481034B2 (en) | 2013-07-09 |
| KR20130042601A (ko) | 2013-04-26 |
| CR20130065A (es) | 2013-03-21 |
| BR112013005423A2 (pt) | 2016-06-07 |
| CA2809375A1 (en) | 2012-03-15 |
| EP2614081B1 (en) | 2016-03-16 |
| WO2012033696A1 (en) | 2012-03-15 |
| GT201300058A (es) | 2014-07-16 |
| CA2809375C (en) | 2016-02-09 |
| AR082641A1 (es) | 2012-12-19 |
| US20130280278A1 (en) | 2013-10-24 |
| US20120058126A1 (en) | 2012-03-08 |
| UA109148C2 (uk) | 2015-07-27 |
| AU2011299443B2 (en) | 2014-06-05 |
| PH12013500432A1 (en) | 2017-08-23 |
| EP2614081A1 (en) | 2013-07-17 |
| MX2013002718A (es) | 2013-05-01 |
| CL2013000607A1 (es) | 2014-04-11 |
| JP2013538813A (ja) | 2013-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI822760B (zh) | 結合ｃｄ４７蛋白的融合蛋白及其應用 | |
| CN113286817B (zh) | Dll3结合蛋白及使用方法 | |
| US11827712B2 (en) | IL13Rα2 binding agents and use thereof | |
| CA2741127C (en) | Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment | |
| ES2914177T3 (es) | Anticuerpos anti-OX40 humanizados y usos de los mismos | |
| CN113603785B (zh) | 新的间皮素抗体和包含其的组合物 | |
| ES2568801T3 (es) | Composiciones de anticuerpos anti-VEGFR-3 | |
| CN101454345A (zh) | 人il-6受体的高亲和力抗体 | |
| CN113614111A (zh) | 用于调节细胞内化的组合物和方法 | |
| AU2020254215B2 (en) | CD3 binding molecules | |
| CN113423830A (zh) | 对muc18特异性的抗体 | |
| ES2949317T3 (es) | Anticuerpo monoclonal antiAggrus, dominio en Aggrus que es necesario para la unión a CLEC-2 y método para la detección del inhibidor de unión de Aggrus-CLEC-2 | |
| KR20240112870A (ko) | 항-cd24 항체 및 이의 용도 | |
| CN113874396B (zh) | 包含抗间皮素抗体、抗cd3抗体或抗egfr抗体的融合蛋白、包含所述融合蛋白的双特异性或三特异性抗体，及其用途 | |
| BR112020017018A2 (pt) | Proteínas de ligação anti-antígeno de mieloma lambda (lma) para tratamento de disordens autoimunes e cânceres que expressem o lma | |
| US20240317885A1 (en) | Anti-tax interacting protein-1 (tip1) binding molecules | |
| KR20240001136A (ko) | IgE 항체를 포함하는 조성물 | |
| CN116761823A (zh) | 靶向gpc3和cd47的双特异性抗体 | |
| HK40054516A (en) | Novel mesothelin antibody and composition comprising the same |